Chris Carpenter joins the R&D exodus out of pharma; George Church's eGenesis selects Jodie Morrison as new CEO
⇨ After spending the last decade in Big Pharma R&D, Chris Carpenter is making the leap to biotech, joining the rising star Rubius as chief medical officer. Carpenter — a former associate professor at Harvard Med, where he ran a lab for years — spent the last six years at GSK, where he wrapped up his stint as a senior VP and head of cancer epigenetics. He jumped from Harvard to Merck to GSK, where he was credited with leading the development of Votrient. And at Merck he worked on MK-4827, which went on to become Tesaro’s PARP drug Zejula. He’s going to one of the best financed upstarts in biotech. Just a few months ago, Cambridge, MA-based Rubius lined up a $120 million round, with plans to develop a full pipeline of new drugs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters